Why "Most Favored Nation" Drug Pricing Hurts Patients and Medical Innovation

As policymakers consider imposing a Most Favored Nation (MFN) model for prescription drug pricing, it's important to understand the effects this approach could have on patients, innovation, and the broader healthcare system. The attached issue guide outlines why MFN—a form of socialist price controls—would do little to reduce out-of-pocket costs for Medicaid patients, while significantly disrupting America’s globally leading biopharmaceutical sector. By discouraging investment in research and development, limiting access to advanced treatments, and undermining the competitive market that fuels medical breakthroughs, MFN policy puts both lives and progress at risk. Use this issue guide to explore the full implications of MFN and how it threatens the very system that has made the U.S. a global leader for pharmaceutical innovation.